Literature DB >> 8501146

The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B.

K R Feingold1, R M Krauss, M Pang, W Doerrler, P Jensen, C Grunfeld.   

Abstract

Plasma low density lipoproteins (LDL) comprise multiple discrete subclasses, differing in size, density, and chemical composition. Gradient gel electrophoresis of LDL has demonstrated three common subclass patterns based on the predominant LDL subclass: large LDL, designated subclass pattern A; small LDL particles, designated subclass pattern B; and an intermediate pattern. Genetic studies have demonstrated that these patterns are inherited, but several lines of evidence suggest that environmental factors are important in the phenotypic expression of the pattern. The LDL B pattern is associated with increased levels of plasma triglyceride, reduced high density lipoprotein (HDL), and obesity. To better define the role of environmental factors on LDL phenotypic expression, we determined LDL patterns in patients with the acquired immunodeficiency syndrome (AIDS), an infection characterized by hypertriglyceridemia and weight loss. Similar to previous studies, plasma triglyceride levels were increased, whereas plasma cholesterol, LDL cholesterol, and HDL cholesterol levels were decreased in the AIDS subjects compared to those in age-matched controls. The percentage of AIDS subjects with the LDL B phenotype was increased 2.5-fold, demonstrating an increased prevalence of the LDL B phenotype in an acquired form of hypertriglyceridemia. For each LDL phenotype in AIDS, serum triglyceride levels were higher than the same phenotypic pattern in controls, with the most marked elevations in triglycerides found in AIDS subjects with the LDL B phenotype. In contrast to what was observed in controls, HDL cholesterol levels were decreased in all AIDS subjects and were unrelated to LDL pattern. Total and LDL cholesterol levels were higher in controls with the LDL B phenotype than in those with the LDL A phenotype, but there was no difference in total and LDL cholesterol in AIDS subjects with LDL B compared to A. On multiple regression analysis in subjects with AIDS, plasma triglyceride levels, age, and HDL cholesterol all contribute to the occurrence of the LDL B phenotype, but elevations in plasma triglyceride levels are the strongest independent predictor. Body mass index was not a predictor of LDL B phenotype in AIDS. These results suggest that disturbances in triglyceride metabolism that are caused by AIDS lead to the appearance of the LDL subclass B phenotype and provide further evidence that environmental or disease states that perturb lipid metabolism can produce an increased prevalence of the LDL B phenotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501146     DOI: 10.1210/jcem.76.6.8501146

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

1.  Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Authors:  K M Wasan; F W Strobel; S C Parrott; M Lynn; W J Christ; L D Hawkins; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

Review 3.  Managing the metabolic and morphologic complications of HIV.

Authors:  M Keith Rawlings; Guillermo Santos
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

Review 4.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

Review 5.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

6.  HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 7.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

Review 8.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

9.  Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.

Authors:  James H Stein; Lauren Komarow; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; Robert A Parker; Francesca J Torriani
Journal:  J Clin Lipidol       Date:  2008-12       Impact factor: 4.766

10.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.